RP
CRL icon

Riverwater Partners’s Charles River Laboratories CRL Stock Holding History

Riverwater Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.6M Buy
+9,292
New +$1.72M 0.53% 67
2024
Q4 		– Sell
-5,643
Closed -$1.09M – 219
2024
Q3 		$1.09M Buy
5,643
+126
+2% +$26.2K 0.54% 57
2024
Q2 		$1.14M Buy
5,517
+1,878
+52% +$426K 0.84% 27
2024
Q1 		$986K Buy
3,639
+32
+0.9% +$7.64K 0.72% 32
2023
Q4 		$853K Buy
3,607
+24
+0.7% +$4.72K 0.67% 40
2023
Q3 		$702K Sell
3,583
-42
-1% -$8.62K 0.64% 40
2023
Q2 		$762K Buy
3,625
+171
+5% +$34K 0.68% 42
2023
Q1 		$697K Buy
3,454
+19
+0.6% +$4.31K 0.64% 46
2022
Q4 		$748K Buy
3,435
+130
+4% +$28.4K 0.64% 41
2022
Q3 		$650K Buy
3,305
+1,232
+59% +$266K 0.65% 48
2022
Q2 		$444K Buy
2,073
+157
+8% +$38.4K 0.45% 69
2022
Q1 		$544K Sell
1,916
-1,900
-50% -$586K 0.9% 47
2021
Q4 		$1.44M Buy
+3,816
New +$1.48M 1.28% 10

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Riverwater Partners's CRL Position: Q1 2026 in Review

Riverwater Partners opened a new position in Charles River Laboratories (CRL) in Q1 2026: 9,292 shares worth $1.6M. The stake represents 0.53% of the portfolio and ranks #67 among its holdings. This is a return to the name: Riverwater Partners previously reported a position in CRL as recently as Q3 2024.

Riverwater Partners first reported a position in CRL in Q4 2021 and has held it in 13 quarters since. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Riverwater Partners held 9,292 shares of Charles River Laboratories worth $1.6M as of Q1 2026.
  • Charles River Laboratories was a new Riverwater Partners position in Q1 2026.
  • Charles River Laboratories made up 0.53% of Riverwater Partners's portfolio in Q1 2026, its #67 holding.
  • Riverwater Partners first reported a position in Charles River Laboratories in Q4 2021 and has held it in 13 quarters since.
  • 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Riverwater Partners's 13F filing for Q1 2026, filed 8 May 2026.